spironolactone has been researched along with Scleroderma, Systemic in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The drug allergy was thus the occasion for the persisting pigment deposition with circumscribed spotty pigmentation of the skin." | 1.27 | [Pigmented exanthema after spironolactone allergy in progressive systemic scleroderma]. ( Luderschmidt, C, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wada, Y | 1 |
| Kobayashi, D | 1 |
| Murakami, S | 1 |
| Oda, M | 1 |
| Hanawa, H | 1 |
| Kuroda, T | 1 |
| Nakano, M | 1 |
| Narita, I | 1 |
| Luderschmidt, C | 2 |
| Altmeyer, P | 1 |
| Goerz, G | 1 |
| Hammer, H | 1 |
| Holzmann, H | 1 |
| Krieg, T | 1 |
| Meigel, WN | 1 |
| Mensing, H | 1 |
1 trial available for spironolactone and Scleroderma, Systemic
| Article | Year |
|---|---|
Spironolactone treatment in scleroderma--a double-blind therapy study.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Scleroderma, Systemic; Spironolactone | 1985 |
2 other studies available for spironolactone and Scleroderma, Systemic
| Article | Year |
|---|---|
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
[Pigmented exanthema after spironolactone allergy in progressive systemic scleroderma].
Topics: Adult; Drug Eruptions; Drug Hypersensitivity; Humans; Male; Pigmentation Disorders; Scleroderma, Sys | 1983 |